Intest Res.  2017 Oct;15(4):511-517. 10.5217/ir.2017.15.4.511.

High C-reactive protein level is associated with high-risk adenoma

• Lee HM
• Cha JM
• Lee JL
• Jeon JW
• Shin HP
• Joo KR
• Yoon JY
• Lee JI

• KMID: 2396401
• DOI: http://doi.org/10.5217/ir.2017.15.4.511

Abstract

BACKGROUND/AIMS
There is substantial evidence supporting a role of inflammation in the pathogenesis of colorectal cancer; however, little is known about the association between serum C-reactive protein (CRP) and the risk of colorectal adenoma. This study was conducted to investigate the association between serum CRP and colorectal adenoma risk.
METHODS
A retrospective cross-sectional study was performed on first-time screening colonoscopies in asymptomatic subjects who also had their serum CRP level measured during a routine health check-up between September 2006 and September 2009 in Korea. Serum CRP level was compared between high-risk and low-risk adenoma groups and independent predictors of high-risk adenoma were analyzed using multivariate regression analysis.
RESULTS
Among the 3,309 eligible patients, the high-risk adenoma group had higher serum CRP levels than the low-risk adenoma group (P=0.000). In addition, patients with a high-risk adenoma were more frequently included in the high CRP group than in the low CRP group (8.6% vs. 4.0%, P<0.001). The prevalence of high-risk adenoma was 3.5 times higher in the highest quartile of CRP level (P=0.000) compared with that in the lowest quartile. In logistic regression analysis, a higher quartile CRP level was found to be an independent risk factor for high-risk adenoma (odds ratio, 1.8; 95% confidence interval, 1.3-2.5; P=0.000).
CONCLUSIONS
High CRP level is associated with high-risk adenoma in both men and women. Our data may support the association between chronic inflammation and colorectal neoplasia, which warrants further investigation.

Keyword

Colon; Inflammation; Neoplasms; C-reactive protein; Colonoscopy

MeSH Terms

Adenoma*
C-Reactive Protein*
Colon
Colonoscopy
Colorectal Neoplasms
Cross-Sectional Studies
Female
Humans
Inflammation
Korea
Logistic Models
Male
Mass Screening
Prevalence
Retrospective Studies
Risk Factors
C-Reactive Protein

Reference

1. Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG, Lee JS. Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treat. 2013; 45:1–14. PMID: 23613665.

2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60:277–300. PMID: 20610543.

3. Burt RW. Colorectal cancer screening. Curr Opin Gastroenterol. 2010; 26:466–470. PMID: 20664346.

4. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy: the National Polyp Study Workgroup. N Engl J Med. 1993; 329:1977–1981. PMID: 8247072.

5. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004; 287:G7–G17. PMID: 15194558.

6. Maggio-Price L, Treuting P, Zeng W, Tsang M, Bielefeldt-Ohmann H, Iritani BM. Helicobacter infection is required for inflammation and colon cancer in SMAD3-deficient mice. Cancer Res. 2006; 66:828–838. PMID: 16424015.

7. Sansbury LB, Millikan RC, Schroeder JC, Moorman PG, North KE, Sandler RS. Use of nonsteroidal antiinflammatory drugs and risk of colon cancer in a population-based, case-control study of African Americans and Whites. Am J Epidemiol. 2005; 162:548–558. PMID: 16093288.

8. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003; 348:891–899. PMID: 12621133.

9. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003; 348:883–890. PMID: 12621132.

10. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993; 328:1313–1316. PMID: 8385741.

11. Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology. 1991; 101:635–639. PMID: 1650315.

12. Ladenheim J, Garcia G, Titzer D, et al. Effect of sulindac on sporadic colonic polyps. Gastroenterology. 1995; 108:1083–1087. PMID: 7698575.

13. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000; 342:1946–1952. PMID: 10874062.

14. Tsilidis KK, Branchini C, Guallar E, Helzlsouer KJ, Erlinger TP, Platz EA. C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer. 2008; 123:1133–1140. PMID: 18528865.

15. Wu J, Cai Q, Li H, et al. Circulating C-reactive protein and colorectal cancer risk: a report from the Shanghai Men’s Health Study. Carcinogenesis. 2013; 34:2799–2803. PMID: 23985781.

16. Toriola AT, Cheng TY, Neuhouser ML, et al. Biomarkers of inflammation are associated with colorectal cancer risk in women but are not suitable as early detection markers. Int J Cancer. 2013; 132:2648–2658. PMID: 23161620.

17. Chiu HM, Lin JT, Chen TH, et al. Elevation of C-reactive protein level is associated with synchronous and advanced colorectal neoplasm in men. Am J Gastroenterol. 2008; 103:2317–2325. PMID: 18844617.

18. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA. 2004; 291:585–590. PMID: 14762037.

19. Rhodes JM, Campbell BJ. Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. Trends Mol Med. 2002; 8:10–16. PMID: 11796261.

20. Crockett SD, Mott LA, Barry EL, et al. C-reactive protein and risk of colorectal adenomas or serrated polyps: a prospective study. Cancer Prev Res (Phila). 2014; 7:1122–1127. PMID: 25145487.

21. Gunter MJ, Cross AJ, Huang WY, et al. A prospective evaluation of C-reactive protein levels and colorectal adenoma development. Cancer Epidemiol Biomarkers Prev. 2011; 20:537–544. PMID: 21212059.

22. Park SK, Park DI, Park JH, et al. C-reactive protein level and colorectal adenoma. Korean J Gastroenterol. 2008; 51:225–231. PMID: 18516001.

23. Ito Y, Suzuki K, Tamakoshi K, et al. Colorectal cancer and serum C-reactive protein levels: a case-control study nested in the JACC Study. J Epidemiol. 2005; 15(Suppl 2):S185–S189. PMID: 16127232.

24. Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on colorectal cancer. Gastroenterology. 2012; 143:844–857. PMID: 22763141.

25. Rogowski O, Zeltser D, Shapira I, et al. Gender difference in C-reactive protein concentrations in individuals with atherothrombotic risk factors and apparently healthy ones. Biomarkers. 2004; 9:85–92. PMID: 15204313.

26. Otake T, Uezono K, Takahashi R, et al. C-reactive protein and colorectal adenomas: Self Defense Forces Health Study. Cancer Sci. 2009; 100:709–714. PMID: 19469014.

27. Kim S, Keku TO, Martin C, et al. Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res. 2008; 68:323–328. PMID: 18172326.

28. Tsilidis KK, Erlinger TP, Rifai N, et al. C-reactive protein and colorectal adenoma in the CLUE II cohort. Cancer Causes Control. 2008; 19:559–567. PMID: 18214695.

29. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005; 115:911–919. PMID: 15867843.

30. Kawada T. Relationships between the smoking status and plasma fibrinogen, white blood cell count and serum C-reactive protein in Japanese workers. Diabetes Metab Syndr. 2015; 9:180–182. PMID: 25801482.

31. Longo-Mbenza B, Nkongo Mvindu H, Kasiam On’kin JB, et al. The deleterious effects of physical inactivity on elements of insulin resistance and metabolic syndrome in Central Africans at high cardiovascular risk. Diabetes Metab Syndr. 2011; 5:1–6. PMID: 22814833.

32. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001; 286:327–334. PMID: 11466099.

33. Effoe VS, Correa A, Chen H, Lacy ME, Bertoni AG. High-sensitivity C-reactive protein is associated with incident type 2 diabetes among African Americans: the Jackson Heart Study. Diabetes Care. 2015; 38:1694–1700. PMID: 26068864.

34. Rampal S, Yang MH, Sung J, et al. Association between markers of glucose metabolism and risk of colorectal adenoma. Gastroenterology. 2014; 147:78–87. PMID: 24632359.

35. Kang HW, Kim D, Kim HJ, et al. Visceral obesity and insulin resistance as risk factors for colorectal adenoma: a cross-sectional, case-control study. Am J Gastroenterol. 2010; 105:178–187. PMID: 19755965.

36. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347:1557–1565. PMID: 12432042.

37. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA. 2003; 290:2945–2951. PMID: 14665655.

38. Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem. 2001; 47:444–450. PMID: 11238295.

39. Meier-Ewert HK, Ridker PM, Rifai N, Price N, Dinges DF, Mullington JM. Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem. 2001; 47:426–430. PMID: 11238292.